|
Evaluating the Scientific Evidence
for Potential Reduced-Risk Tobacco Products
Core Committee Meeting
April 27-28, 2005
Bethesda, MD
 Agenda
|
| |
Wednesday, April 27, 2005
| |
Information Gathering: Open Session
| |
8am to 5pm
Important:
Due to overwhelming response, the information gathering session has been extended to 5pm.
A boxed lunch will be provided.
Welcome and Participant Introductions
| |
Michael Falk, Ph.D.
Executive Director, LSRO
|
Overview of the LSRO Reduced Risk Review Project
| |
Catherine St. Hilaire, Ph.D.
Project Leader, Reduced Risk Review Project
|
KEYNOTE SPEAKER
Laboratory animal models for assessing the relative health hazards of complex combustion/pyrolysis emissions
| |
Joe L. Mauderly, D.V.M.
Lovelace Respiratory Research Institute
|
GUEST SPEAKERS
Comparative potency method for cancer risk assessment of complex combustion emissions
| |
Joellen Lewtas, Ph.D.
University of Washington
|
Prenatal exposure to cigarette smoke increases tumor susceptibility of the offspring: a toxicological model
| |
Judith T. Zelikoff, Ph.D.
New York University School of Medicine
|
Genotoxic effects of nicotine in human target cells of carcinogenesis
| |
Norbert Kleinsasser, M.D., Ph.D.
University of Regensburg, Germany
|
Feasibility of breath condensate lipids and eicosanoids as non-invasively collected biomarker predictors of pulmonary pathobiology
| |
David C. White, M.D., Ph.D.
University of Tennessee
|
REGISTERED SPEAKERS
PREPS testing and the smaller tobacco companies
| |
John Lauterbach, Ph.D., D.A.B.T.
Lauterbach & Associates
|
British American Tobacco's approach to harm reduction and reduced-risk products
| |
David O'Reilly
British American Tobacco
|
Evaluating smoking behavior and human smoke exposure for reduced risk products
| |
Eian Massey
British American Tobacco
|
The evolving scientific paradigm for evaluating reduced risk products
| |
Derek Mariner
British American Tobacco
|
The need for scientific engagement in harm reduction
| |
Anna-Lisa M. Fisher
British American Tobacco
|
Biosynthec technology to reduce tobacco harm
| |
Christian Rolando
Biosynthec, Paris
|
Biologic tests to prove efficacy of Biosynthec technology for tobacco harm reduction
| |
Kroum Alexandrov
Biosynthec, Paris
|
The future of tobacco harm reduction technologies
| |
Iman Emami
Biosynthec, Paris
|
Toxicological Testing Required for PREPs
| |
David Johnson
Swedish Match North America
|
Risk reduction and smokeless tobacco
| |
James Dillard
U.S. Smokeless Tobacco Company
|
The role of blending and processing in developing reduced-risk cigarettes with acceptable smoking qualities
| |
Fawky M. Abdallah, Ph.D.
Fawky Abdallah Company, Inc.
|
|
|
Executive Session - following Open Session
|
Thursday, April 28, 2005
|
|
